|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miyahara R, Niwa Y, Matsuura T, Maeda O,
Ando T, Ohmiya N, Itoh A, Hirooka Y and Goto H: Prevalence and
prognosis of gastric cancer detected by screening in a large
Japanese population: Data from a single institute over 30 years. J
Gastroenterol Hepatol. 22:1435–1442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Correa P: Gastric cancer: Overview.
Gastroenterol Clin North Am. 42:211–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takahashi T, Saikawa Y and Kitagawa Y:
Gastric cancer: Current status of diagnosis and treatment. Cancers
(Basel). 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K,
Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs
in serum: A novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res. 18:997–1006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hamada S, Satoh K, Fujibuchi W, Hirota M,
Kanno A, Unno J, Masamune A, Kikuta K, Kume K and Shimosegawa T:
miR-126 acts as a tumor suppressor in pancreatic cancer cells via
the regulation of ADAM9. Mol Cancer Res. 10:3–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hashiguchi Y, Nishida N, Mimori K, Sudo T,
Tanaka F, Shibata K, Ishii H, Mochizuki H, Hase K, Doki Y and Mori
M: Down-regulation of miR-125a-3p in human gastric cancer and its
clinicopathological significance. Int J Oncol. 40:1477–1482.
2012.PubMed/NCBI
|
|
10
|
Chen L, Li H, Han L, Zhang K, Wang G, Wang
Y, Liu Y, Zheng Y, Jiang T, Pu P, et al: Expression and function of
miR-27b in human glioma. Oncol Rep. 26:1617–1621. 2011.PubMed/NCBI
|
|
11
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: miR-27b targets PPARγ to inhibit growth, tumor progression and
the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishihara T, Seki N, Inoguchi S, Yoshino H,
Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M
and Enokida H: Expression of the tumor suppressive miRNA-23b/27b
cluster is a good prognostic marker in clear cell renal cell
carcinoma. J Urol. 192:1822–1830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song J, Bai Z, Han W, Zhang J, Meng H, Bi
J, Ma X, Han S and Zhang Z: Identification of suitable reference
genes for qPCR analysis of serum microRNA in gastric cancer
patients. Dig Dis Sci. 57:897–904. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khromova N, Kopnin P, Rybko V and Kopnin
BP: Downregulation of VEGF-C expression in lung and colon cancer
cells decelerates tumor growth and inhibits metastasis via multiple
mechanisms. Oncogene. 31:1389–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bera A, VenkataSubbaRao K, Manoharan MS,
Hill P and Freeman JW: A miRNA signature of chemoresistant
mesenchymal phenotype identifies novel molecular targets associated
with advanced pancreatic cancer. PLoS One. 9:e1063432014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olofsson B, Jeltsch M, Eriksson U and
Alitalo K: Current biology of VEGF-B and VEGF-C. Curr Opin
Biotechnol. 10:528–538. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang X, Chen X, Fang J and Yang C:
Overexpression of both VEGF-A and VEGF-C in gastric cancer
correlates with prognosis, and silencing of both is effective to
inhibit cancer growth. Int J Clin Exp Pathol. 6:586–597.
2013.PubMed/NCBI
|
|
23
|
Zhu P, Zhang J, Chen Q, Wang J and Wang Y:
Expression of vascular endothelial growth factor-C in gastric
carcinoma and the effect of its antisense gene transfection on the
proliferation of human gastric cancer cell line SGC-7901. Am J
Surg. 204:78–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Skobe M, Hawighorst T, Jackson DG, Prevo
R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K and Detmar
M: Induction of tumor lymphangiogenesis by VEGF-C promotes breast
cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steven AS, Achen MG, Jussila L, Baldwin ME
and Alitalo K: Lymphangiogenesis and cancer metastasis. Nat Rev
Cancer. 2:573–583. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tammela T and Alitalo K:
Lymphangiogenesis: Molecular mechanisms and future promise. Cell.
140:460–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dias S, Choy M, Alitalo K and Rafii S:
Vascular endothelial growth factor (VEGF)-C signaling through FLT-4
(VEGFR-3) mediates leukemic cell proliferation, survival, and
resistance to chemotherapy. Blood. 99:2179–2184. 2002. View Article : Google Scholar : PubMed/NCBI
|
